Karen Briscoe

Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial

Viviana Galimberti, Bernard F. Cole, Giuseppe Viale et al. · The Lancet Oncology · 2018 · 565 citations

Medicine, Oncology, Surgery +17

Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression

Georgina V. Long, Jeffrey S. Weber, James Larkin et al. · JAMA Oncology · 2017 · 185 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in

Anna K. Nowak, W. Joost Lesterhuis, Peey‐Sei Kok et al. · The Lancet Oncology · 2020 · 169 citations · Full text

Medicine, Oncology, Pharmacology +12

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann et al. · The Lancet Oncology · 2020 · 162 citations

Medicine, Gynecology, Oncology +14

Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial

Peter Grimison, Antony Mersiades, Adrienne Kirby et al. · Annals of Oncology · 2020 · 153 citations · Full text

Medicine, Oncology, Pharmacology +14